FRI0110 A Phase I Pharmacokinetic Study Comparing SB5, An Adalimumab Biosimilar, And Adalimumab Reference Product (Humira®) in Healthy Subjects

Abstract

BackgroundSB5, a biosimilar to adalimumab reference product (ADL), has an identical amino acid sequence, similar physicochemical and in vitro functional properties to its reference drug.ObjectivesThe primary objective of this study...